Camelid TB Serology Quarterly Report: 1st April 2020 to 30th June 2020
Source: environment.data.gov.uk (2024-10-03)

Camelid TB Serology Quarterly Report. Camelid TB Serology Quarterly Report.

Camelid TB Serology
Quarterly Report
Number: 21
Report Period 1st April to 30th June 2020
Issued 01 July 2020

Submission Reason
Explanation
APHA /DEFRA
At Government expense
Parallel Test:
PAR-TB
TB breakdown herd with confirmed M. bovis infection (including Wales where Officially
TB Free Withdrawn [OTFW] status is determined on epidemiological grounds)
PAR-SUS
TB strongly suspected but not currently confirmed by laboratory culture – herd under
restrictions
PAR-TRC
Forward  tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in
Wales only co-located on the same premises with infected cattle, sheep, deer, goats
& pigs)
Serial Test:
SER-CONT
Herd not under restriction but contiguous to a TB-infected herd
SER-COL
Herd not under restriction but co-located with an infected herd of cattle, deer, goats
etc. (Eng & Scot only)
SER-EPI
Herd not under restriction but TB tested due to an epidemiological link with a known
infected herd (e.g. back-tracing)
Commercial/Private
At Owner expense
SER-MVT
Pre- or post-movement test
SER-EXP 
Pre-export test
SER-DIAG
Diagnostic to exclude TB from a differential diagnoses in a herd not restricted (TB
strongly suspected)
SER-RHT
Monitoring - voluntary routine testing (herd nor restricted)
Quarterly Camelid Serology Report
Test Criteria
The camelid TB serology (antibody) test generally comprises two separate antibody tests in a test package that can be
applied flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test
interpretation respectively. The sensitivity and specificity values of combined antibody testing for camelids were described
under AHVLA Project FT1477 (see Rhodes et al., 2012) and re-assessed in May 2018 to show the following test
performance;
Table 1 – High Sensitivity / Parallel test options:
IDEXX /DPP VetTB
ENFER 2-SPOT/DPP VetTB
IDEXX/ENFER 2-SPOT
% Se
74
71
75
95% C.I.
65.4-82.6
62.1-79.9
66.5-83.5
% Sp
96
96.7
97.3
95% C.I.
93.8-98.2
95.8-99.4
95.4-99.1
Fishers Exact [2-sided] test showed no significant difference in sensitivity or specificity between any of these three test options.
Table 2 – High Specificity / Serial test options:
Fishers Exact [2-sided] test showed no significant difference in test sensitivity or specificity between these two test options.
ENFER 4-SPOT
IDEXX/DPP VetTB
% Se
60
56
95% C.I.
50.4-69.9
46.3-65.7
% Sp
99.66
100
95% C.I.
98.9-100
Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko,
K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and
antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.

Quarterly Camelid Serology Report
01 Jul 2020
Table 1a
Country
No.
Samples
Tested
England
517
Total for Q2
517
Number of Samples tested and Submission Reason  2020 Q2 (April - June)
Table 1b
Submission
Reason
No. Samples
Tested
Parallel
PAR-SUS
2
PAR-TB
414
Parallel
Sum:
416
Serial
SER-COL
7
SER-CONT
80
Serial
Sum:
87
Commercial/Private Testing
SER-MVT
9
Commercial/Private Testing
Sum:
9
                   
4
SER-CHK
1
Sum:
5
Total for Q2
Sum:
517

Quarterly Camelid Serology Report
01 Jul 2020
Table 2a
Country
No.
Samples
Tested
England
691
Wales
62
Total for Q2
753
Number of Samples tested and Submission Reason 2020 up to end of Q2 (January - June)
Table 2b
APHA/DEFRA
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
2
PAR-TB
422
Parallel
Sum:
424
Serial
SER-COL
29
SER-CONT
268
Serial
Sum:
297
Commercial/Private Testing
SER-MVT
24
SER-RHT
3
Commercial/Private Testing
Sum:
27
                   
4
SER-CHK
1
Sum:
5
Total for 2020 up to end
of Q2
753

Quarterly Camelid Serology Report
01 Jul 2020
Table 3a
Submissions Received and Test Positivity in 2020 Q2
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
1
2
2
100.0%
PAR-TB
2
414
40
9.7%
Parallel
3
416
42
10.1%
Serial
SER-COL
2
7
0
0
SER-CONT
16
80
4
5.0%
Serial
18
87
4
4.6%
Commercial/Private Testing
SER-MVT
4
9
0
0
Commercial/Private Testing
4
9
0
0
                   
1
4
0
0
SER-CHK
1
1
1
100.0%
2
5
1
20.0%
England Total
27
517
47
9.1%
Totals for Q2
27
517
47
9.1 %
Test Positivity in 2020 Q2 (April - June)

Quarterly Camelid Serology Report
01 Jul 2020
Table 3b
Submissions Received and Test Positivity in 2020 up to the end of Q2
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
1
2
2
100.0%
PAR-TB
4
422
40
9.5%
Parallel
5
424
42
9.9%
Serial
SER-COL
9
29
1
3.4%
SER-CONT
36
206
4
1.9%
Serial
45
235
5
2.1%
Commercial/Private Testing
SER-MVT
8
24
0
0
SER-RHT
1
3
0
0
Commercial/Private Testing
9
27
0
0
                   
1
4
0
0
SER-CHK
1
1
1
100.0%
2
5
1
20.0%
England Total
61
691
48
6.9%
Wales
Serial
SER-CONT
5
62
2
3.2%
Serial
5
62
2
3.2%
Wales Total
5
62
2
3.2%
Totals up to
end Q2
66
753
50
6.6 %
Test Positivity in 2020 up to end of Q2 (January - June)

Quarterly Camelid Serology Report
01 Jul 2020
Submissions Received in 2020 up to end of Q2
Analysis
Analysis Description
Q1
No.
samples
tested
Q2
No.
samples
tested
Totals up to end Q2
TC0503
Camelid TB Enferplex - 2
Spot
6
416
422
TC0603
Camelid TB Enferplex - 4
Spot
101
49
150
TC0611
Dhembio DPP VetTB lateral
flow rapid antibody test
129
59
188
TC0867
Camelid TB Antibody
ELISA
135
461
596
Table 4: Number of samples Tested by Test Code